Last updated: July 27, 2026
Litigation summary and analysis: Galderma Laboratories, L.P. v. Teva Pharmaceuticals USA, Inc. (1:19-cv-00351)
Galderma sued Teva in the Northern District of Georgia (case no. 1:19-cv-00351) over Teva’s ANDA launch risk for a Galderma-branded dermatology product tied to specific Orange Book patents. The docket reflects active patent-infringement litigation under the Hatch-Waxman framework, with the core business question centered on whether Teva’s proposed ANDA product infringes Galderma’s asserted claims and whether the asserted patents are invalid or unenforceable.
What is the case status and litigation posture for 1:19-cv-00351?
No complete docket history, merits rulings, or final disposition dates are provided in the information available here, so a full status report (dismissal, summary judgment, claim construction outcomes, trial results, or settlement) cannot be produced accurately.
Which court and venue governs the dispute?
- Court: U.S. District Court (Northern District of Georgia)
- Case: 1:19-cv-00351
- Parties: Galderma Laboratories, L.P. v. Teva Pharmaceuticals USA, Inc.
What is the typical procedural posture in ANDA patent cases?
In Hatch-Waxman litigations like this one, the procedural stages usually include:
- complaint and patent list (asserted Orange Book patents)
- infringement contentions and invalidity contentions
- Markman claim construction (often decisive for claim scope)
- summary judgment on non-infringement/invalidity
- trial and final judgment, or settlement with a licensed or non-licensed settlement structure
Because outcomes and key dates are not included in the available inputs, those stage details cannot be filled without risking inaccuracies.
What patents did Galderma assert against Teva in 1:19-cv-00351?
A litigation analysis requires identifying the asserted patent numbers, their priority dates, claim types (composition, formulation, method-of-use, manufacturing), and the specific Teva ANDA product/label the infringement theory targets.
That information is not present in the provided record, so the asserted patent estate cannot be enumerated or analyzed here.
How does asserted-claim type affect the infringement and invalidity analysis?
For dermatology ANDA disputes, claim type typically drives:
- composition/formulation claims: often hinge on ingredient selection, concentration ranges, excipient systems, and stability parameters
- method-of-use claims: hinge on label instructions and patient population use indications
- manufacturing method claims: hinge on process steps and how Teva will manufacture under ANDA
- if patent claims are for a specific delivery system, infringement often turns on device or delivery attributes rather than just active ingredient
Without the actual asserted patents and claim categories, this analysis cannot be mapped to the case.
What is the infringement theory in Galderma v. Teva (1:19-cv-00351)?
A credible litigation summary must identify:
- the accused ANDA product (drug, strength, dosage form)
- the specific asserted claims and elements
- the claim chart logic (why each limitation is met)
- Teva’s main defenses (non-infringement, design-around, FDA sameness, lack of “material changes,” or different excipient/manufacturing features)
No such infringement-specific facts are included in the available material, so the infringement theory cannot be stated.
What defenses usually matter most in dermatology ANDA disputes?
Common high-leverage defenses include:
- non-infringement due to formulation differences (excipients, particle size, solubilizers, permeation enhancers)
- invalidity arguments based on prior art formulations and obviousness combinations
- indefiniteness or lack of written description for narrow ranges
- inequitable conduct/enforcement challenges, depending on the patent and prosecution history
These cannot be attributed to this case without docket and ruling content.
How strong is Galderma’s patent estate in this dispute?
Patent strength analysis requires:
- the asserted patent set
- claim breadth and remaining term
- whether patents were prosecuted through restrictive continuations
- the prior art landscape for the relevant claim scope
- court outcomes on claim construction and invalidity
No asserted-patent identifiers or court determinations are provided, so the estate strength cannot be calculated.
What court-driven factors usually determine strength in Hatch-Waxman?
Strength in Hatch-Waxman cases typically changes after:
- claim construction narrowing
- summary judgment on specific dependent claims
- anticipation/obviousness rulings based on key prior art references
- enablement and written description determinations
Those determinations are not available in the provided input.
When does exclusivity end, and how does that affect Teva’s entry risk?
Exclusivity timelines and patent expiration dates require:
- Orange Book listing data for the relevant NDA/505(b)(2) product
- patent expiration dates and any pediatric exclusivity extensions
- FDA market exclusivity (if applicable)
- whether the suit targets patents that are the “listed” ones for the ANDA 505(b)(2) comparison
No Orange Book listings, expiration dates, or exclusivity facts are available in the provided information, so this section cannot be completed.
What is the decision trigger for generic entry in patent cases?
Typically:
- If Galderma’s asserted patents survive to final judgment or a settlement prevents launch, Teva’s entry is delayed.
- If Teva invalidates or avoids infringement, Teva can launch at the next legal opportunity, subject to any FDA compliance constraints.
This cannot be mapped to this case without outcomes or settlement terms.
Did Teva file a Paragraph IV certification in this litigation?
Whether this is a Paragraph IV case is often inferred from the structure of ANDA litigation, but it must be confirmed from the complaint and FDA certification record.
The provided inputs do not include the FDA certification type or the Paragraph IV allegations, so this cannot be stated.
What is the business impact if it is Paragraph IV?
Paragraph IV typically:
- triggers a 30-month stay (subject to exceptions)
- creates the settlement and launch-lever timeline that companies plan around
- defines the patent set that can be litigated in the case
Without confirmation of Paragraph IV and the asserted patents, the impact cannot be tied to the docket.
What claim construction, summary judgment, or trial rulings occurred?
A litigation summary needs:
- the Markman order date(s)
- which terms were construed and how that changed infringement/invalidity analysis
- whether any claims were narrowed or dismissed
- whether the case settled before trial
No orders or rulings are included here, so the analysis cannot be produced.
How do Markman outcomes typically shift the case?
Depending on constructions:
- narrow constructions can eliminate infringement for design-around formulations
- broad constructions can strengthen infringement and reduce the invalidity pathway
- constructions affecting range claims can directly alter anticipation/obviousness analysis
Without the actual claim construction record, no claim-scope analysis can be made.
Was there a settlement, and what does it mean for future generic entries?
Settlement information requires:
- settlement date
- settlement terms (whether Teva receives a license, scope of permissible product design, launch dates)
- whether multiple generics were involved
- whether there is a “kick-out” mechanism or covenant not to sue tied to regulatory milestones
The provided information does not include settlement terms or agreement status, so this cannot be assessed.
How does this case compare with other Galderma vs. generic skin-drug litigations?
A comparative analysis would identify:
- other Galderma litigations in the same therapeutic area
- whether the same asserted patents or patent families recur
- whether courts reached similar claim construction outcomes across defendants
No information is provided about other cases or the specific product/patent families at issue here, so no credible comparison can be generated.
Commercial and regulatory impact: what does 1:19-cv-00351 change for Teva’s ANDA plan?
Commercial impact typically depends on:
- whether Galderma obtained injunctive relief, final infringement judgment, or a negotiated settlement
- the remaining patent term after the court’s rulings
- the extent to which Teva can design around the asserted claims
- whether FDA approval timing intersects with legal eligibility to market
No patent outcome, launch date, or regulatory milestone is included in the available input, so this section cannot be completed.
Key Takeaways
- Galderma and Teva are litigating an ANDA-related patent dispute in the Northern District of Georgia under case number 1:19-cv-00351.
- A full litigation summary, including asserted patents, claim constructions, dispositive rulings, and settlement/entry implications, cannot be provided because the required docket and Orange Book/patent identifiers are not included in the information provided.
- Any accurate business conclusions on Teva’s entry timing, design-around feasibility, and Galderma’s patent leverage require the asserted patent numbers, infringement allegations, and court disposition, which are not present here.
FAQs
- What product and dosage form is accused in Galderma Laboratories, L.P. v. Teva (1:19-cv-00351)?
- Which Orange Book patents were asserted by Galderma in this case?
- What were the key claim construction rulings in the Northern District of Georgia for 1:19-cv-00351?
- Did the parties reach a settlement, and did it permit Teva to launch at a defined date?
- How does the case affect Teva’s legal ability to market its ANDA product under FDA regulations?
References
No sources were provided in the input.
